Hannah Joseph Hospital (HANNAH) Q2 FY27's Growth Pauses as Profit Holds Steady
Revenue and profit held steady sequentially in Q2 FY27, marking a pause after strong year-on-year growth driven by lower interest costs and a focus on neurosciences.
Hannah Joseph Hospital posted steady revenue and profit in Q2 FY27, a sequential pause after robust annual growth. The quarter's profit growth outpaced sales, aided by a sharp fall in interest expense and stable margins.
For Hannah Joseph Hospital, a leading neurosciences center in South Tamil Nadu, the September quarter was about holding the gains from a strong previous period. Revenue and net profit both held steady compared to the March quarter, marking a sequential pause after robust annual growth.
The numbers show a year-on-year rise but a flat quarter-on-quarter performance. Revenue reached ₹50 crore, up 16.3% from a year ago but unchanged from Q4 FY26. Net profit stood at ₹6 crore, a 20% annual increase, also matching the prior quarter. The net profit margin improved slightly to 12%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|
| Period | Sep 2026 | Sep 2025 |
| Revenue (₹ Cr) | 50.0YoY +16% | 43.0 |
| Profit (₹ Cr) | 6.0YoY +20% | 5.0 |
| Net Profit Margin (%) | 12.0YoY +3.4% | 11.6 |
The leverage from a lighter balance sheet
Profit growth outpaced revenue because of a significant drop in finance costs. Interest expense fell by 50% year-on-year, according to the analysis. A report from newboard.in notes the company cut its borrowings last year, improving its interest cover. This financial efficiency provided a clear boost to the bottom line.
Operational growth continues to be anchored in complex brain and spine surgeries and trauma care. The hospital's own pharmacy and diagnostic services, which keep patient spending in-house, contributed to revenue stability. Bed occupancy was around 43% in FY26, reports newboard.in, leaving room to treat more patients without adding capacity.
Awaiting the next growth phase
Management has not provided explicit financial guidance, notes a StockFin.ai analysis. The immediate focus is on executing funded expansion plans. These include building a radiation oncology centre, funded by IPO proceeds, and opening a public pharmacy branch in Madurai this fiscal year.
The competitive landscape in South Tamil Nadu is intensifying. The Hindu BusinessLine reports Kauvery Hospitals plans to enter Madurai, highlighting the race for market share in tier-2 cities. Hannah Joseph's clinical reputation in neurosciences remains its key differentiator amid this expansion.
Key Points
- Revenue and profit were flat sequentially at ₹50 crore and ₹6 crore, pausing after strong annual growth.
- A 50% year-on-year drop in interest expense helped profit grow faster than sales, improving financial efficiency.
- The hospital operates with spare bed capacity, providing a lever for future volume growth without major capital spend.
- Expansion into cancer care and a retail pharmacy branch, funded by its IPO, are the near-term catalysts to watch.
Hexa Perspective
This quarter reflects a business in a holding pattern, digesting past gains before its new capacities come online. The flat sequential numbers are not a concern if they represent a plateau before the planned oncology centre opens, which could significantly alter the revenue mix.
The stock trades at a P/E of 23.2, a steep discount to the industry average of 85.8, as per the payload. This gap suggests the market is yet to price in the potential of its specialty-led model and funded expansion, or is discounting execution risks in a competitive region. The next few quarters will test its ability to convert clinical expertise into scalable, profitable growth.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
